Literature DB >> 1450318

Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.

J C Gris1, J F Schved, B Branger, P Aguilar-Martinez, F Vécina, R Oulès, C Sarlat, J Fourcade.   

Abstract

We describe a 50-year-old man with a severe acquired haemorrhagic syndrome. He had slightly prolonged clotting times using bovine thrombin, human thrombin and reptilase. His plasma contained a polyclonal IgG which interfered with the generation of fibrin monomers without inhibiting the aggregation of preformed monomers. The inhibitor delayed thrombin-induced fibrinopeptide A release. The IgG bound to insolubilized synthetic fibrinopeptide A (one binding site per molecule) and, with higher affinity, to fibrinogen (two binding sites per molecule). It did not bind to insolubilized fibrin monomers. The IgG did not impair the catalytic activity of thrombin toward a small synthetic substrate but inhibited the binding of thrombin to fibrinogen without binding to thrombin. The binding of the anti-fibrinopeptide A autoantibody to fibrinogen might have impaired thrombin-induced fibrinogen to fibrin conversion in vivo. This may have favoured the reported haemorrhagic syndrome which was associated with severe chronic renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450318     DOI: 10.1097/00001721-199210000-00002

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  A novel mutation in exon 2 of FGB caused by c.221G>T substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis.

Authors:  Abdul A Shlebak; Alexia D Katsarou; George Adams; Fiona Fernando
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.